Fatih M. Uckun

23.0k total citations
637 papers, 18.2k citations indexed

About

Fatih M. Uckun is a scholar working on Immunology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Fatih M. Uckun has authored 637 papers receiving a total of 18.2k indexed citations (citations by other indexed papers that have themselves been cited), including 196 papers in Immunology, 188 papers in Molecular Biology and 154 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Fatih M. Uckun's work include Acute Lymphoblastic Leukemia research (146 papers), HIV/AIDS drug development and treatment (95 papers) and Toxin Mechanisms and Immunotoxins (89 papers). Fatih M. Uckun is often cited by papers focused on Acute Lymphoblastic Leukemia research (146 papers), HIV/AIDS drug development and treatment (95 papers) and Toxin Mechanisms and Immunotoxins (89 papers). Fatih M. Uckun collaborates with scholars based in United States, Türkiye and Germany. Fatih M. Uckun's co-authors include Osmond J. D’Cruz, T.K. Venkatachalam, Damian E. Myers, L Tuel-Ahlgren, Alexei Vassilev, Sanjive Qazi, E. Sudbeck, Paul S. Gaynon, Harland N. Sather and Martha G. Sensel and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Fatih M. Uckun

622 papers receiving 17.6k citations

Peers

Countries citing papers authored by Fatih M. Uckun

Since Specialization

Citations

This map shows the geographic impact of Fatih M. Uckun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fatih M. Uckun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fatih M. Uckun more than expected).

Fields of papers citing papers by Fatih M. Uckun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fatih M. Uckun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fatih M. Uckun. The network helps show where Fatih M. Uckun may publish in the future.

Co-authorship network of co-authors of Fatih M. Uckun

This figure shows the co-authorship network connecting the top 25 collaborators of Fatih M. Uckun. A scholar is included among the top collaborators of Fatih M. Uckun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fatih M. Uckun. Fatih M. Uckun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes 2023 ·International Journal of Molecular Sciences ·Fatih M. Uckun, Sanjive Qazi	2
2	High Intra-Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma 2023 ·Cancers ·Fatih M. Uckun, Sanjive Qazi, Vuong Trieu	6
3	Upregulated Expression of ErbB1 in Diffuse Large B-Cell Lymphoma as a Predictor of Poor Overall Survival Outcome 2023 ·Journal of Personalized Medicine ·Sanjive Qazi, Fatih M. Uckun	1
4	ERBB1/EGFR and JAK3 Tyrosine Kinases as Potential Therapeutic Targets in High-Risk Multiple Myeloma 2022 ·SHILAP Revista de lepidopterología ·Fatih M. Uckun, Sanjive Qazi	5
5	Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination 2022 ·The Oncologist ·Deniz Can Güven, Taha Koray Şahin, Serkan Akın, Fatih M. Uckun	13
6	Augmented Expression of the IL3RA/CD123 Gene in MLL/KMT2A-Rearranged Pediatric AML and Infant ALL 2022 ·MDPI (MDPI AG) ·Sanjive Qazi, Fatih M. Uckun	1
7	Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436 2021 ·Cancers ·Fatih M. Uckun, Justin M. Watts, Alice S. Mims, Prapti A. Patel, Eunice S. Wang, Paul J. Shami, Elizabeth H. Cull, (unknown), Christopher R. Cogle, Tara L. Lin	7
8	Targeting TGF-beta pathway with COVID-19 Drug Candidate ARTIVeda/PulmoHeal Accelerates Recovery from Mild-Moderate COVID-19 2021 ·Clinical Investigation ·Vuong Trieu, (unknown), Prashant Rahate, (unknown), (unknown), (unknown), Fatih M. Uckun	0
9	Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma 2021 ·Cancers ·Fatih M. Uckun	40
10	A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome 2021 ·Cancers ·Fatih M. Uckun, Tara L. Lin, Alice S. Mims, Prapti A. Patel, (unknown), Anoush Shahidzadeh, Paul J. Shami, Elizabeth H. Cull, Christopher R. Cogle, Justin M. Watts	31
11	A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia 2019 ·Cancers ·Fatih M. Uckun, Christopher R. Cogle, Tara L. Lin, Sanjive Qazi, Vuong Trieu, Gary J. Schiller, Justin M. Watts	26
12	Recurrent or Refractory High-Grade Gliomas Treated by Convection-Enhanced Delivery of a TGFβ2-Targeting RNA Therapeutic: A Post-Hoc Analysis with Long-Term Follow-Up 2019 ·Cancers ·Fatih M. Uckun, Sanjive Qazi, (unknown), Vuong Trieu	30
13	Wilms’ Tumor Gene (WT1) Expression in Cytogenetically Distinct Subsets of AML 2018 ·Sanjive Qazi, Fatih M. Uckun, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2
14	Recent Advances in Anogenital Antiretroviral Microbicides and Multimodal Delivery Systems 2012 ·Journal of AIDS & Clinical Research ·Osmond J. D’Cruz, Fatih M. Uckun	2
15	Stat3-Syk Molecular Complex as A Target for Anti-Cancer Nanomedicines 2012 ·Journal of Nanomedicine & Nanotechnology ·Fatih M. Uckun	1
16	Structural Requirements for Potent Anti-Human Immunodeficiency Virus (HIV) and Sperm-Immobilizing Activities of Cyclohexenyl Thiourea and Urea Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase1 2002 ·Biology of Reproduction ·Osmond J. D’Cruz, T.K. Venkatachalam, Chen Mao, Sanjive Qazi, Fatih M. Uckun	18
17	Clinical Pharmacokinetics of the CD19 Receptor‐Directed Tyrosine Kinase Inhibitor B43‐Genistein in Patients with B‐Lineage Lymphoid Malignancies 1999 ·The Journal of Clinical Pharmacology ·Chun‐Lin Chen, Alexandra M. Levine, (unknown), (unknown), Yoav H. Messinger, (unknown), Frederick D. Goldman, (unknown), James T. Casper, Fatih M. Uckun	20
18	Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies 1998 ·Cancer ·Fatih M. Uckun, James B. Nachman, Harland N. Sather, Martha G. Sensel, Peter Kraft, Peter G. Steinherz, Beverly Lange, Raymond J. Hutchinson, Gregory H. Reaman, Paul S. Gaynon, Nyla A. Heerema	1
19	Allograft and Autograft Purging Using Immunotoxins in Clinical Bone Marrow Transplantation for Hematologic Malignancies 1993 ·Journal of Hematotherapy ·Fatih M. Uckun, Damian E. Myers	3
20	Heterogeneity of cultured leukemic lymphoid progenitor cells from B cell precursor acute lymphoblastic leukemia (ALL) patients. 1987 ·Journal of Clinical Investigation ·Fatih M. Uckun, John H. Kersey, K Gajl-Peczalska, Nyla A. Heerema, Arthur J. Provisor, D. Haag, Gerald Gilchrist, C. W. Song, D Arthur, James S. Roloff	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact